Clinical Trial Update: Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating verteporfin photodynamic therapy added to ranibizumab versus ranibizumab alone for subfoveal choroidal neovascularization in macular de…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: Novartis | Conditions: Macular Degeneration, Choroidal Neovascularization | Phase 3 | Status: COMPLETED | Results posted: 2011-04-19